Chaturbhuj Devidas N, Hingankar Nitin K, Srikantiah Padmini, Garg Renu, Kabra Sandhya, Deshmukh Pravin S, Jadhav Sushma D, Thorat Smita R, Datkar Sharda R, Mehta Preeti, Ingole Nayana, Mathur Meenakshi, Ramachandran Anita, Haldar Partha, Reddy D C S, Bachani Damodar, Rao Sujatha, Tripathy Srikanth P, Paranjape Ramesh S
National AIDS Research Institute, Bhosari, Pune, India.
AIDS Res Hum Retroviruses. 2010 Aug;26(8):927-32. doi: 10.1089/aid.2010.0032.
A survey for transmitted HIV drug resistance (HIVDR) was conducted according to WHO guidelines among clients newly diagnosed with HIV-1 infection at two voluntary counseling and testing centers (VCTC) in Mumbai. HIVDR testing was performed using the ViroSeq RT-PCR method (Abbott). Out of 50 successfully amplified and sequenced specimens, analysis of the first 34 consecutively collected specimens revealed no nucleoside reverse transcriptase inhibitor, nonnucleoside reverse transcriptase inhibitor, or protease inhibitor mutations from the 2007 WHO list of mutations for surveillance of transmitted HIVDR, indicating that the prevalence of transmitted HIVDR to all three drug classes was <5% among recently infected VCTC clients in Mumbai. The phylogenetic analysis revealed that all samples belonged to HIV-1 subtype C. Continued ART program monitoring and further evaluation of transmitted HIV drug resistance in coming years are essential in Mumbai as well as in other regions of the country in which ART is being scaled up rapidly.
根据世界卫生组织的指南，在孟买的两个自愿咨询和检测中心（VCTC），对新诊断出感染HIV-1的患者进行了传播性HIV耐药性（HIVDR）调查。使用ViroSeq RT-PCR方法（雅培公司）进行HIVDR检测。在50个成功扩增和测序的样本中，对最初连续收集的34个样本进行分析，结果显示，根据2007年世界卫生组织传播性HIVDR监测突变列表，未发现核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂或蛋白酶抑制剂突变，这表明在孟买最近感染的VCTC患者中，传播性HIVDR对所有三类药物的流行率均<5%。系统发育分析表明，所有样本均属于HIV-1 C亚型。在孟买以及该国其他正在迅速扩大抗逆转录病毒治疗（ART）规模的地区，持续进行ART项目监测并在未来几年对传播性HIV耐药性进行进一步评估至关重要。
